

SCORE Search Results Details for Application
10578781 and Search Result
20081104 154454 us-10-578-781-1.rng.

Score Home Page	Retrieve Application List	SCORE System Overview	SCORE FAQ	Comments / Suggestions
---------------------------------	---	---------------------------------------	---------------------------	--

This page gives you Search Results detail for the Application 10578781 and Search Result 20081104_154454_us-10-578-781-1.rng

Go Back to previous page

GenCore version 6.3
Copyright (c) 1993 - 2008 Biocceleration Ltd.

QM nuclei - nuclei search, using sw model

Run on: November 4, 2008, 17:10:32 ; Search time 243 Seconds
(without alignments)
44258.760 Million cell updates/sec

Scoring table: IDENTI TY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 11806651 seqs. 7113014948 residues

Total number of bits satisfying chosen parameters: 23613302

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post - processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Dat abase : N_Geneseq_200808
1: geneseqn1980s:
2: geneseqn1990s:
3: geneseqn2000: *
4: geneseqn2001a: *
5: geneseqn2001b: *
6: geneseqn2002a:
7: geneseqn2002b:
8: geneseqn2003a:
9: geneseqn2003b: *
10: geneseqn2003c: *
11: geneseqn2003d:
12: geneseqn2004a:
13: geneseqn2004b:
14: geneseqn2004c:
15: geneseqn2004d: *
16: geneseqn2004e: *
17: geneseqn2004f: *
18: geneseqn2005a:
19: geneseqn2005b:
20: geneseqn2005c:
21: geneseqn2006a:

22: geneseqn2006b:
 23: geneseqn2006c:
 24: geneseqn2006d:
 25: geneseqn2007a:
 26: geneseqn2007b:
 27: geneseqn2007c:
 28: geneseqn2007d:
 29: geneseqn2008:
 *

Pred. Nb. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query				ID	Description
		Match	Length	DB			
1	756	100.0	756	18	AE00728	Aea00728	Brevibacteri
2	273.4	36.2	665	6	ABK78469	Abk78469	Bacillus
3	192.2	25.4	1438	12	ADN60500	Adn60500	B. lichen
4	178.2	23.6	777	21	AEH93992	Aeh93992	Streptococci
5	173.8	23.0	381	6	ABK74144	Abk74144	Bacillus
6	147	19.4	631	6	ABK74048	Abk74048	Bacillus
7	78	10.3	1110	12	ADH97013	Adh97013	S. pneumoniae
8	78	10.3	1110	18	AEC13368	Aec13368	Streptococcus
9	76.4	10.1	915	12	ADK44581	Adk44581	Streptococcus
10	76.4	10.1	915	21	AEJ68509	Aej68509	Streptococcus
11	76.4	10.1	915	21	AEJ75484	Aej75484	Streptococcus
12	76.4	10.1	915	21	AEJ82844	Aej82844	Streptococcus
13	76.4	10.1	915	21	AELO5163	Ael05163	Streptococcus
14	76.4	10.1	915	21	AEL12413	Ael12413	Streptococcus
15	76.4	10.1	915	21	AEL50821	Ael50821	Streptococcus
16	76.4	10.1	915	25	AEM07844	Aem07844	Streptococcus
17	76.4	10.1	915	25	AEM60066	Aem60066	Streptococcus
18	76.4	10.1	915	25	AEM86645	Aem86645	Streptococcus
19	76.4	10.1	915	25	AG 20663	Ag120663	Streptococcus
20	76.4	10.1	915	25	AGN48202	Agn48202	Streptococcus
21	76.4	10.1	915	25	AEN55537	Aen55537	Streptococcus
22	76.4	10.1	915	25	AEN04034	Aen04034	Streptococcus
23	76.4	10.1	915	25	AG 76906	Ag176906	Streptococcus
24	76.4	10.1	915	25	AEN08741	Aen08741	Streptococcus
25	76.4	10.1	915	25	AGV09876	Agv09876	Streptococcus
26	76.4	10.1	915	25	AGV21123	Agv21123	Streptococcus
27	76.4	10.1	915	25	AJE78366	Aje78366	Streptococcus
28	76.4	10.1	915	25	AJE70154	Aje70154	Streptococcus
29	76.4	10.1	915	25	AJE86340	Aje86340	Streptococcus
30	76.4	10.1	915	25	AJE95472	Aje95472	Streptococcus
31	76.4	10.1	915	25	AJE61089	Aje61089	Streptococcus
32	76.4	10.1	915	25	AGV40930	Agv40930	Streptococcus
33	76.4	10.1	915	25	AGV46355	Agv46355	Streptococcus
34	76.4	10.1	915	25	AJF01903	Ajf01903	Streptococcus
35	76.4	10.1	915	25	AJF07993	Ajf07993	Streptococcus
36	76.4	10.1	915	25	AJF13317	Ajf13317	Streptococcus
37	76.4	10.1	915	25	AJF53284	Ajf53284	Streptococcus
38	76.4	10.1	915	25	AJF18960	Ajf18960	Streptococcus
39	76.4	10.1	915	25	AJG97788	Ajg97788	Streptococcus
40	76.4	10.1	915	25	ALK14103	Alk14103	S. pneumoniae
41	76.4	10.1	915	25	ALT08207	Al108207	Streptococcus
42	76.4	10.1	915	25	ANK69294	Ank69294	Streptococcus
43	76.4	10.1	915	25	ANJ76477	Anj76477	S. pneumoniae
44	76.4	10.1	915	25	ANK74634	Ank74634	Streptococcus
45	76.4	10.1	915	26	ANN03548	Ann03548	S. pneumoniae

ALIGNMENTS

RESULT 1

AEA00728
 ID AEA00728 standard; DNA; 756 BP.
 XX
 AC AEA00728;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE *Brevibacillus choshensis* DNA #1.
 XX
 KW Cell culture; *Brevibacillus choshensis*; gene; ds.
 XX
 OS *Brevibacillus choshensis*.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..756
 FT /tag= a
 FT /product= "B. choshensis protein #1"
 XX
 PN WO2005045005-A1.
 XX
 PD 19-MAY-2005.
 XX
 PE 08-NOV-2004; 2004WO-JP016912.
 XX
 PR 11-NOV-2003; 2003JP-00381606.
 XX
 PA (HGET) HI GETA SHOU KK.
 XX
 PI Hanagata H, Nishijyo T;
 XX
 WPI : 2005-366840/37.
 DR P-PSDB; AEA00729.
 XX
 PT New *Brevibacillus choshensis*, that does not form spores and which shows low extracellular or intracellular protease activity, useful as host for producing recombinant protein.
 XX
 PS Claim 4; SEQ ID NO 1; 103pp; Japanese.
 XX
 CC The invention relates to a *Brevibacillus choshensis* HPD31-SP3 (FERMBP-08479), which does not form spores and which has mycological characteristics such as cell size and rod shape and physiological characteristics such as negative for nitrate reduction and positive for citric acid utilization, oxidase and catalase, and showing low extracellular protease activity. The invention also relates to a transformed *B. choshensis* using a vector containing the gene encoding the protein of the invention. *B. choshensis* is useful as a host for producing a recombinant protein and for producing a protein by culturing a transformed host. It has decreased extracellular protein degradation activity when compared with other strains. This sequence represents *B. choshensis* DNA of the invention.
 XX
 SQ Sequence 756 BP; 207 A; 166 C; 211 G; 172 T; 0 U; 0 Other;

Query Match 100.0% Score 756; DB 18; Length 756;
 Best Local Similarity 100.0% Pred. No. 3e-234;
 Matches 756; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	ATGGGTGCCATATCAAAATGCGAGTCACCAATTCTGACCAATGACCAAGTGAAAGAT	60
Db	1	ATGGGTGCCATATCAAAATGCGAGTCACCAATTCTGACCAATGACCAAGTGAAAGAT	60
Qy	61	TTGATAGCCAAGGCCAACGCTGCCGATAACGGATGCCAGCTGAGCTTCTCGTGAATAGCAAT	120
Db	61	TTGATAGCCAAGGCCAACGCTGCCGATAACGGATGCCAGCTGAGCTTCTCGTGAATAGCAAT	120
Qy	121	ATCAGACTGGCTGGTCCGTCGTCAGCGGCTTATCAACCGCGGTATGAAGCGGATGAT	180
Db	121	ATCAGACTGGCTGGTCCGTCGTCAGCGGCTTATCAACCGCGGTATGAAGCGGATGAT	180

Qy	181	TTGTTTCAGATCGTTGCCATTGGCTCAAGGCCGTTGACAAGTTGATCTTCTGAC 240
Db	181	TTGTTTCAGATCGTTGCCATTGGCTCAAGGCCGTTGACAAGTTGATCTTCTGAC 240
Qy	241	GATGTGAGATTTOGACTATGGGTGCCAATGATCATCGGAGAAATTCAACGCTTTTG 300
Db	241	GATGTGAGATTTOGACTATGGGTGCCAATGATCATCGGAGAAATTCAACGCTTTTG 300
Qy	301	CGCGATGACCGTAACGGTTAAGGTCACTCGTCAAGAAACACCGAATAAGGTGGG 360
Db	301	CGCGATGACCGTAACGGTTAAGGTCACTCGTCAAGAAACACCGAATAAGGTGGG 360
Qy	361	CGATCAAAGGATGAAATTGTACAACGAAATTGGCGGTGCCCGGAGATCGCAGAAGTGGCA 420
Db	361	CGATCAAAGGATGAAATTGTACAACGAAATTGGCGGTGCCCGGAGATCGCAGAAGTGGCA 420
Qy	421	GAAGCAGTGGGAATTCACGCGGAGGAAGTAGTCCTTGCGCAAGGCCAACAGAGCGCT 480
Db	421	GAAGCAGTGGGAATTCACGCGGAGGAAGTAGTCCTTGCGCAAGGCCAACAGAGCGCT 480
Qy	481	TCTCCATCATGAGACCGTTTGAAAATGAGCGATCCATCACACTGATCGATCAG 540
Db	481	TCTCCATCATGAGACCGTTTGAAAATGAGCGATCCATCACACTGATCGATCAG 540
Qy	541	ATAGCGGATGAAGGTGTAACAAAGTGGTTGAGAAAATTGCGTTGAAGGAGCGGATCAGC 600
Db	541	ATAGCGGATGAAGGTGTAACAAAGTGGTTGAGAAAATTGCGTTGAAGGAGCGGATCAGC 600
Qy	601	AGGCTGAGCGACGGTGGACAGCTCATOGCTCACTGCGCTTAAAGGATCAGACACAG 660
Db	601	AGGCTGAGCGACGGTGGACAGCTCATOGCTCACTGCGCTTAAAGGATCAGACACAG 660
Qy	661	TCTGAGGTACAGAGCGCTCTAGGGATTTCAGGGTCCAGGTCTGGGTCTGGAAAAGGGT 720
Db	661	TCTGAGGTACAGAGCGCTCTAGGGATTTCAGGGTCCAGGTCTGGGTCTGGAAAAGGGT 720
Qy	721	ATCCTGCTAACGATCAAGGAGCAAATTGAACATTAG 756
Db	721	ATCCTGCTAACGATCAAGGAGCAAATTGAACATTAG 756

RESULT 2

ABK78469

ID ABK78469 standard; DNA; 665 BP.

XX

AC ABK78469;

XX

DT 13- AUG- 2002 (first entry)

XX

DE *Bacillus clausii* genomic sequence tag (GST) #1312.

XX

KW Differential gene expression; genomic sequenced tag; GST;

KW altered culture condition; environmental stress;

KW physiological provocation; ds.

XX

OS *Bacillus clausii*.

XX

PN WO200229113-A2.

XX

PD 11- APR- 2002.

XX

PF 05- OCT- 2001; 2001WO-US031437.

XX

PR 06- OCT- 2000; 2000US- 00680598.

PR 27- MAR- 2001; 2001US- 0279526P.

XX

PA (NOVO) NOVOZYMES BIOTECH INC.

PA (NOVO) NOVOZYMES AS.

XX

PI Berka R, Clausen IG;

XX

DR WPI ; 2002-416684/44.

XX

PT Monitoring differential expression of several genes in first *Bacillus* cell relative to expression of same genes in one or more second *Bacillus* cells, by using substrate containing *Bacillus* genomic sequenced tag array.

XX

PS

Claim 11; SEQ ID NO 5760; 200pp; English.

XX

CC

The invention describes a method of monitoring differential expression of genes in a first *Bacillus* cell relative to expression of the genes in other *Bacillus* cells, comprising hybridising labelled nucleic acid probes isolated from *Bacillus* cells to a substrate containing array of *Bacillus* genomic sequenced tags (GST), examining the array, and determining relative gene expression by an observed hybridisation reporter signal of a spot in the array. The method is useful for measuring the expression of genes in a first *Bacillus* cell relative to expression of the same genes in one or more second *Bacillus* cells. The method is useful for monitoring global expression of several genes from a *Bacillus* cell, discovering new genes, identifying possible functions of unknown open reading frames and monitoring gene copy number variation and stability. Monitoring changes in expression of genes may be used to provide a representation of the way in which *Bacillus* cells adapt to changes in culture conditions, environmental stress or other physiological provocation. Extensive follow-up characterisation is unnecessary, when one spot on an array equals one gene or one open reading frame, since sequence information is available. This sequence represents a genomic sequence tag (GST) used in the method part of the printed specification, but was obtained in the electronic format directly from WPO at ftp://wipo.int/pub/publi shed_pct_sequences

XX

SQ

Sequence 665 BP; 210 A; 134 C; 159 G; 161 T; 0 U; 1 Other;

Query

Match

36.2%

Score 273.4;

DB 6;

Length 665;

Best Local Similarity 67.4%

Pred. No. 1.9e-77;

Matches 399; Conservative 0;

Mismatches 192;

Indels 1;

Gaps 1;

Qy

37 CTGACCAATGACCAAGTGAAGAATTGATAGCCAAGAGCCAAGCTGGCGATACGGATGCA 96

Db

40 CTATCGATAAACAACTGAAAGAGCTTATTGAAAAAAAGCGAACAGAACACAGAAGCA 99

Qy

97 OGTGAGCTTCCTCGTGAATAGCAATATCAGACTGGTCTGGTGGTGGTGGTGGTGGTGGT 156

Db

100 CGGGATTCGATCGTCAACCATAACACAAGTCTCGTCCTGGTCAGTGGTCAACGTTTTG 159

Qy

157 AACCGCGGTATGAAACCGGTGATTTGTTTCAAGTCAGTCGGTTGCTTGGCTCAAGGCC 216

Db

160 AATCGGGTTATGAGGCAAGTGAACCTTTTCAAAATTGGCTGGATTGGTTAAATTAGCT 219

Qy

217 GTTGACAAGTCGATCTTGTACGATGTCAGATTTGGACCTATGGGGTGCGCAATGATC 276

Db

220 GTGCGACAAATTGACCTTCTACGACGTTGAAATTTCACGCTATGCTGTGCGCGATGATT 279

Qy

277 ATCGGAGAAATTCAACCGCTTTTGCGCGATGACCGTAACGGTTAAGGTCAAGTCAGTCAGTGGTAA 336

Db

280 ATTTGGTGAATCAACCGTTCTGGCGCGATGATGGCGACAGTGAAGTAACCGGTCCT 339

Qy

337 AAAGAACACCGAATAAGGTGGGGGATCAAAGGATGAATTGACAAGCAATTGCGCGT 396

Db

340 AAAGAATTAAAGCAATAAAACCGAACGAAACGAAACTGACGAAACCGCTGGCGGG 399

Qy

397 GCGCGGACGATCGCAGAAGTGGCAGAAGCGAGTGGGAATCACGGGAGGAGTAGTCCTT 456

Db

400 GCAACGACCAATTAAATGAGATCGTGAACATTAGCGCTGAGCGCTGAGGAAATTGTATTT 459

Qy

457 GCGCAAGAGCCACCGAGACCGGCTTCTCCATOCATGAGAACGTTTTGAAAATGACGGC 516

Db 460 CCTGGAGATCCAAACCGGACCTTGTCTCAATCCATGAAACGGTTATGAAAATGACGGC 519
 Qy 517 GATCCCATCACACTGATCGATCAGATAAGGGATGAAGGTGTGAACAAGTGGTTTGAGAAA 576
 Db 520 GATCGATTACACTTCTAGATCAAATTGGCGACCACTCACAAAGTCAAATGGTTGACAAG 579
 Qy 577 ATGGCCCTGAAGGACCCCATCAGCAGCTGACCGAGGTGAGCAAGTCATGG 628
 Db 580 ATTGCTTTAAAGAACCGATTGGACCTTGGCGANAGGGAGGGCTAATTG 630

RESULT 3

ADN60500

ID ADN60500 standard; DNA; 1438 BP.

XX

AC ADN60500;

XX

DT 01-JUL-2004 (first entry)

XX

DE B. licheniformis sporulation related polynucleotide, seq id 172.

XX

KW Mutant host cell; sporulation; oxidoreductase; transferase; hydrolase;

LYase; isomerase; ligase; gene; ds.

XX

OS Bacillus licheniformis.

XX

PN WO2003087148-A2.

XX

PD 23-OCT-2003.

XX

PF 25-MAR-2003; 2003WO-DK000200.

XX

PR 10-APR-2002; 2002DK-00000533.

XX

PA (NOVO) NOVOZYMES AS.

XX

PI Andersen JT, Jorgensen ST, Rasmussen MD, Olsen PB, Clausen IG.

XX

DR WPI; 2004-122131/12.

DR P-PSDB; ADN60501.

XX

PT A Bacillus licheniformis mutant host cell for producing a product of

PT interest e.g. vitamins, antibiotics and enzymes.

XX

CAI m 1; SEQ ID NO 172; 319pp; English.

XX

CC The invention relates to a *Bacillus licheniformis* mutant host cell
 CC derived from a parent *B. licheniformis* host cell. The mutant host cell is
 CC mutated in one or more genes encoding one or more polypeptides involved
 CC in sporulation. The host cell comprises one or more heterologous genes
 CC present in at least two copies, encoding one or more heterologous
 CC polypeptides. The heterologous genes are stably integrated into the
 CC genome of the cell without leaving any antibiotic resistance marker genes
 CC at the site of integration. The heterologous genes are transcribed from a
 CC heterologous promoter or from an artificial promoter, and are comprised
 CC in an operon, preferably a polycistronic operon. The heterologous
 CC polypeptide is an antimicrobial peptide, or a fusion peptide comprising a
 CC peptide part which in its native form has antimicrobial activity. The
 CC heterologous polypeptide is an enzyme, preferably a secreted enzyme. The
 CC enzyme is an enzyme of a class selected from the group of enzyme classes
 CC consisting of oxidoreductases (EC 1), transferases (EC 2), hydrolases (EC
 CC 3), lyases (EC 4), isomerases (EC 5), and ligases (EC 6). The *Bacillus*
 CC *licheniformis* is useful in a process for producing at least one product
 CC of interest, comprising cultivating a *B. licheniformis* mutant host cell
 CC in a suitable medium, whereby the said product is produced. The process
 CC further comprises isolating or purifying the product of interest. The
 CC current sequence represents a *B. licheniformis* sporulation related
 CC polynucleotide.

RESULT 4

AEH93992

| D AEH93992 standard; cDNA; 777 BP.

XX 12 45100000

AC AEH93992;
XX

xx DT 27-11-2006 (first entry)

27-JUL-2008 (111st ed)

DE SigG coding sequence.
XX
KW ss; gene; protein production; sigma factor; RNA polymerase;
KW alkaline protease; fadD

XX at Kartine pre ease, Food

OS Bacillus sp.; KSM-9865.
 XX
 FH Key Location Qualifiers
 FT CDS 1. .777
 FT /*tag= a
 FT /product = "Si gG"

XX

PN JP2006136221
WY

xx
BD 01-JUN-2006

FD 01-JUN-2000.
XX

XX
 PR 10- NOV- 2004; 2004JP- 00326973.
 XX
 PA (KAOS) KAO CORP.
 XX
 PI Sumitomo N, Okuda T, Taki mur a Y, Sat o T, Kobayashi T;
 XX
 DR WPI : 2006-385028/ 40.
 DR P-PSDB; AEH93994.
 XX
 PT Novel sporulation related gene encoding SigE protein or SigG protein
 PT having al kaline protease activity, useful in foodstuffs such as alcohol c
 PT beverage, bean paste, soy sauce, pharmaceuticals and cosmetics.
 XX
 PS Cai m 1; SEQ ID NO 2; 15pp; Japanese.
 XX
 CC This sequence represents the SigG sequence which encodes the sigma factor
 CC which is a subunit of RNA polymerase. A microorganism transformed with
 CC the SigE or SigG sequence is useful for producing a protein or
 CC polypeptide having al kaline protease activity. The sigma peptides are
 CC useful in foodstuffs e.g. alcohol c beverage, bean paste, soy sauce,
 CC pharmaceuticals and cosmetics. The protein having al kaline protease
 CC activity can be produced efficiently using non-sporulated microorganism.
 XX
 SQ Sequence 777 BP; 264 A; 123 C; 189 G; 201 T; 0 U; 0 Other;
 Query Match 23.6% Score 178.2; DB 21; Length 777;
 Best Local Similarity 53.9% Pred. No. 1.8e-46;
 Matches 391; Conservative 0; Mismatches 328; Indels 6; Gaps 1;
 Qy 31 CCATTTCTGACCAATGACCAAGT GAAAGATTTGATGCCAAGGCCAAGCTGGCGATAAGC 90
 Db 49 CCTGTTTGAAGAAATGAAAGAATGOGGAAGTTATTCGTTGAAATGCAAGGGAGAACCTT 108
 Qy 91 GATGCCAGTCTGGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCTGGTCTGGTCTGGC 150
 Db 109 TCTGCAAGACAAAAAGCTCGTGAATGGAAACCAAGGCTGGTCTAAAGTGTATTCAACGG 168
 Qy 151 TTTATCAACCGCGGGTATGAAACGGATGATTTGTTTCAGATGGGTTCCATTGGCTTGCTC 210
 Db 169 TTTAACAAACCGTGGTGAATTGTAGATGACTTATTCAGTAGGCTCCATGGGTTAAATG 228
 Qy 211 AAGGCGGTGACAAGTTCGATCTTCTGAGATGTGAGATTTGACCTATGGCGTGGCA 270
 Db 229 AAGTCGATTGATAATTTCGACTGGGTCTGAGATTTGACCTATGCAATATGGAGTACCA 288
 Qy 271 ATGATCATCGGAGAAATTCAACCGCTTTGGCGCGATGACGGTAAGGTTAAGGTCACTGCA 330
 Db 289 ATGATAATCGGAGATAACGGCTATCTACAGATAATAATCGATCAGGTATCGCGC 348
 Qy 331 TCGTTAAAGAACAGCGAATAAGGTGGCGCGATCAACGGATCAATTGTACAACCGAACATTC 390
 Db 349 TCATTGGTGTATTGGCTACAAAGGCCCTGAGGTCAAGGAAAGGCTGATGAGTGAACACA 408
 Qy 391 GGOGTGCGCGGCGAOGATCGCAGAAGTGGCGCAAGCAGTGGGAATCACCGCGGAGGAAAGTA 450
 Db 409 TCAAGGGAGCGTCAACCGAGAAATTCAAAAGTACTTGAGTACCGCATGAGGAGATT 468
 Qy 451 GTCCTTGGCGAAGAGGCAACCGAGGCCCTGCTCCATCCATGAGACCGTTTGGAAAT 510
 Db 469 GTTTTGGCTTAAATGCTATTCAAGGATCGCGTGGCTATTGGCTATCTATAATGAT 528
 Qy 511 GAOGGGAGATCCACACTGATCGATCAGATAGGGATGAAGGTGTGAA-----CAAG 564
 Db 529 GGTGGAGATCGATTATGATGAGGATCAATCAGTGGCAAGAAAGAACAAAGATATCCAA 588
 Qy 565 TGGTTTGAGAAAATTGCGTTGAAAGGAGGCCATCAGCAGGCTGAGCGGCGTGGCGAGCTC 624
 Db 589 TGGATAGAAGAGATACCACTAAAGAAGGTATGAGACGCTCAATGACACGGAAAACCTC 648

Qy	625	ATCGTCTAOCCTGGCTATTACAAGGATCAGACACAGCTCTGAGGTACCGAGACGGCTTAGGG	684
Db	649	ATTTTAAGAAAACGGTTTTTCAGGGAAAACCCAAATCGAAGTACCTGATGAAATCGGG	708
Qy	685	ATTTCCGAGGTCCAGGTCTGGGTCTGGAAAAGCGTATCCTGCTAACGATCAAGGAGCAA	744
Db	709	ATATCCCAACACAAGTGTCAAGACTTGAAAGGCTGCAATCAACAGATGAATAAAAT	768
Qy	745	ATTGA	749
Db	769	ATTC	773

RESULT 5

ABK74144

| D ABK74144 standard; DNA; 381 BP.

XX

AC ABK74144;

XX

DT 13- AUG 2002 (first entry)

XX

DE *Bacillus licheniformis* genomic sequence tag (GST) #1435.

XX

KW Differential gene expression; genomic sequenced tag; GST;

KW altered culture condition; environmental stress;

KW physiological provocation; ds.

XX

CS *Bacillus licheniformis*.

XX

PN WO200229113-A2.

XX

PD 11- APR 2002.

XX

PF 05- OCT- 2001; 2001WO-US031437.

XX

PR 06- OCT- 2000; 2000US-00680598.

PR 27- MAR- 2001; 2001US-0279526P.

XX

PA (NOVO) NOVOZYMES BIOTECH INC.

PA (NOVO) NOVOZYMES AS.

XX

PI Berka R, Clausen IG;

XX

WI ; 2002-416684/44.

XX

PT Monitoring differential expression of several genes in first *Bacillus* cell relative to expression of same genes in one or more second *Bacillus* cells, by using substrate containing *Bacillus* genomic sequenced tag array.

XX

PS Claim 4; SEQ ID NO 1435; 200pp; English.

XX

The invention describes a method of monitoring differential expression of genes in a first *Bacillus* cell relative to expression of the genes in other *Bacillus* cells, comprising hybridising labelled nucleic acid probes isolated from *Bacillus* cells to a substrate containing array of *Bacillus* genomic sequenced tags (GST), examining the array, and determining relative gene expression by an observed hybridisation reporter signal of a spot in the array. The method is useful for measuring the expression of genes in a first *Bacillus* cell relative to expression of the same genes in one or more second *Bacillus* cells. The method is useful for monitoring global expression of several genes from a *Bacillus* cell, discovering new genes, identifying possible functions of unknown open reading frames and monitoring gene copy number variation and stability. Monitoring changes in expression of genes may be used to provide a representation of the way in which *Bacillus* cells adapt to changes in culture conditions, environmental stress or other physiological provocation. Extensive follow-up characterisation is unnecessary, when one spot on an array equals one

CC gene or one open reading frame, since sequence information is available.
 CC This sequence represents a genomic sequence tag (GST) used in the method
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from WPO at ftp://ftp.wipo.int/pub/publi shed_pct_sequences

XX
 SQ Sequence 381 BP; 109 A; 91 C; 94 G; 87 T; 0 U; 0 Other;

Query Match 23.0% Score 173.8; DB 6; Length 381;
 Best Local Similarity 66.9% Pred. No. 3.4e-45;
 Matches 247; Conservative 0; Mismatches 122; Indels 0; Gaps 0;

Qy 50 AAGTGAAGAGATTGTATAGCCAGGCCAAGCTGCCGATACCGATGCCAGTGAGCTTCCTCG 109
 Db 13 AAGTGAAGAGACTGATTAACACAGGCCAGAACCGCGATCAAAAGCAAGGCAACCTCTCA 72

Qy 110 TGAATAGCAATATCAGACTGGCTCGGTOCGTCGTCAGGCCCTTATCAACCGCGGGATG 169
 Db 73 TAGAAAAAAACATGGCTCTGGTTGGTCGTCAGGTTTGTGAACAGAGGCTATG 132

Qy 170 AACGGGATGATTGTTCAGATCGGTTGCATTGCCCTGCTCAAGGCCGTTGACAAGTTG 229
 Db 133 AGGCTGAOGACCTCTTCAAAATGCCCTGCATGCCCTCTTGAAGTGGTGGACAAATTG 192

Qy 230 ATCTTCTGTAOGATGTGAGATTGTTGACACTATCGGGTGCCTAACGCGAACTATTC 289
 Db 193 ATCTTCTGTAOGATGTGAGATTGTTGACACTACCGCGGTTGGATGATTATCGGGAGATTC 252

Qy 290 AACGCTTTTGGCGATGACGGTAAGGTTAAGGTCAGTOATCGTTAAAGAAACAGGCA 349
 Db 253 AGGGTTTATCAGAGATGAGGGAAACGCTAAAGTGAACCGCTGCCCTGAAAGAACCTGGCA 312

Qy 350 ATAAGGTGGCGCGATCAAAGGATGAATTGTACAAGCAATTGGCGGTGCCCCCAOGATOG 409
 Db 313 ACAAAATGGCGGGGAAAGAOGACGCTTCCAAAGTCAAACGGCGGATTGGAOOGITTC 372

Qy 410 CAGAAGTGG 418
 Db 373 AGGAAATG 381

RESULT 6

ABK74048

ID ABK74048 standard; DNA; 631 BP.

XX

AC ABK74048;

XX

DT 13-AUG-2002 (first entry)

XX

DE *Bacillus licheniformis* genomic sequence tag (GST) #1339.

XX

KW Differential gene expression; genomic sequenced tag; GST;

KW altered culture condition; environmental stress;

KW physiological provocation; ds.

XX

CS *Bacillus licheniformis*.

XX

PN WO200229113-A2.

XX

PD 11-APR-2002.

XX

PF 05-OCT-2001; 2001WO-US031437.

XX

PR 06-OCT-2000; 2000US-00680598.

PR 27-MAR-2001; 2001US-0279526P.

XX

PA { NOVO } NOVOZYMES BIOTECH INC.

PA { NOVO } NOVOZYMES AS.

XX

Pl Berka R, Clausen IG;

XX WPI ; 2002-416684/44.

XX
PT Monitoring differential expression of several genes in first *Bacillus* cell relative to expression of same genes in one or more second *Bacillus* cells, by using substrate containing *Bacillus* genomic sequenced tag
XX
array.

PS Claim 4; SEQ ID NO 1339; 200pp; English.

XX

CC The invention describes a method of monitoring differential expression of genes in a first *Bacillus* cell relative to expression of the genes in other *Bacillus* cells, comprising hybridising labelled nucleic acid probes isolated from *Bacillus* cells to a substrate containing array of *Bacillus* genomic sequenced tags (GST), examining the array, and determining relative gene expression by an observed hybridisation reporter signal of a spot in the array. The method is useful for measuring the expression of genes in a first *Bacillus* cell relative to expression of the same genes in one or more second *Bacillus* cells. The method is useful for monitoring global expression of several genes from a *Bacillus* cell, discovering new genes, identifying possible functions of unknown open reading frames and monitoring gene copy number variation and stability. Monitoring changes in expression of genes may be used to provide a representation of the way in which *Bacillus* cells adapt to changes in culture conditions, environmental stress or other physiological provocation. Extensive follow-up characterisation is unnecessary, when one spot on an array equals one gene or one open reading frame, since sequence information is available. This sequence represents a genomic sequence tag (GST) used in the method of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WPO at ftp://wipo.int/pub/publi/shed_pct_sequences

XX

SQ Sequence 631 BP; 203 A; 121 C; 161 G; 146 T; 0 U; 0 Other;

Query Match 19.4% Score 147; DB 6; Length 631;
Best Local Similarity 56.8% Pred. No. 2.3e-36;
Matches 270; Conservative 0; Mismatches 205; Indels 0; Gaps 0;

Qy	77	AAGCTGGCGATAACGGATGCAAGTGAGCTTCCTGGAATAGCAATATCAGACTGGTCTGGT	136
Db	98	ATGAAGGAGACAAACAGGGAGAGAGAAAAGCTTGTAAAGCGCAATTGCGGCTTGTCTAA	157
Qy	137	CCGTOGTCCAGCGCTTATCAACCGGGGTATGAAGGGATGATTGTTGTTTCAAGATGGTT	196
Db	158	GGCTCATTCAAAGGTTAAACAACAGAGGAGAAATATGTTGATGACTTATTCCAAGTCGGCT	217
Qy	197	GCATTGGCTTGTCAAGGCGTTGACAAGGTTCGATCTTCTGACGATGTGAGATTTGGA	256
Db	218	GGATCGGACTAAATGAAATCAATTGATAATTTCGACCTGACGCAACATGTTAAGTTTCAA	277
Qy	257	CCTATCGGGTGCACATGATCATCGGACAAATTCAACCGCTTTGCGCGATGACGGTACGG	316
Db	278	CATATCGCTGACCAATGATCATCGGACAAATCCCGAGATATTGCGGATAACACCGGA	337
Qy	317	TTAACGGTCAGTCGATCGTTAAAGAAAACCGGAATAGTGGCGCGATCAACGGATGAAT	376
Db	338	TGCGCGTCAACGGTCACTCAACGGATATCGCGTACAAAGCGCTTCAAGTGAAGAACGGC	397
Qy	377	TGTACAAGCAATTGGCGTGGCGGCAAGCGGACCGAGCTGGTGGCGAGGAGCTGGGAATCA	436
Db	398	TGATCAGTGAGACAAACCGGGACCGAGCTGCTCAGGAGATGCTAAAGACGTTGAAGTGT	457
Qy	437	CGCGCGAGGAAAGTAGTCCTTGCGCAACAGCGCAACCGAGCGGCTTCCCTCATCGATGAGA	496
Db	458	CCCATGAAGAAATGTTTGCGCTGACCGATTCAGATGCTGATCTTGTGTTGAGC	517
Qy	497	CGTTTTTGAAGAATGACGGCGATCCCATCACACTGATGATCACAGATACGGCGATGA	551

D0 518 CGATTTACAATGAOGGAGGAGATCGGATTTATGTCATGGATCAAATCAGCGATGA 572

RESULT 7

ADH97013

ID ADH97013 standard; DNA; 1110 BP.

XX

AC ADH97013;

XX

DT 06-MAY-2004 (first entry)

XX

DE S. pneumoniae RNA polymerase sigma-70 factor gene #2.

XX

KW anti bacterial; anti inflammatory; gastrointestinal; antilcer;
KW anti diarrhoeic; opthalmological; enzyme inhibitor; antisense therapy;
KW vaccine; microbial target; modulator; furuncle; pneumonia; gastritis;
KW peptic ulcer disease; diarrhoea; meningitis; bacteraemia; conjunctivitis;
KW toxic shock syndrome; gene; ds.

XX

CS Streptococcus pneumoniae.

XX

PN WO2003102190-A2.

XX

PD 11-DEC-2003.

XX

PF 02-JUN-2003; 2003WO-CA000786.

XX

PR 31-MAY-2002; 2002US-0384634P.
PR 31-MAY-2002; 2002US-0385157P.
PR 04-JUN-2002; 2002US-0385542P.
PR 04-JUN-2002; 2002US-0385611P.
PR 04-JUN-2002; 2002US-0385747P.
PR 04-JUN-2002; 2002US-0385750P.
PR 04-JUN-2002; 2002US-0385752P.
PR 04-JUN-2002; 2002US-0385773P.
PR 04-JUN-2002; 2002US-0385780P.
PR 04-JUN-2002; 2002US-0385785P.
PR 04-JUN-2002; 2002US-0385797P.
PR 05-JUN-2002; 2002US-0385962P.
PR 05-JUN-2002; 2002US-0386022P.
PR 05-JUN-2002; 2002US-0386024P.
PR 05-JUN-2002; 2002US-0386087P.
PR 05-JUN-2002; 2002US-0386141P.
PR 05-JUN-2002; 2002US-0386350P.
PR 05-JUN-2002; 2002US-0386586P.
PR 06-JUN-2002; 2002US-0386368P.
PR 06-JUN-2002; 2002US-0386369P.
PR 06-JUN-2002; 2002US-0386436P.
PR 06-JUN-2002; 2002US-0386441P.
PR 06-JUN-2002; 2002US-0386528P.
PR 06-JUN-2002; 2002US-0386573P.
PR 06-JUN-2002; 2002US-0386834P.
PR 31-JUL-2002; 2002US-0399839P.
PR 31-JUL-2002; 2002US-0399861P.
PR 31-JUL-2002; 2002US-0399969P.
PR 31-JUL-2002; 2002US-0399970P.
PR 31-JUL-2002; 2002US-0399983P.
PR 31-JUL-2002; 2002US-0399984P.
PR 31-JUL-2002; 2002US-0399985P.
PR 01-AUG-2002; 2002US-0400154P.
PR 01-AUG-2002; 2002US-0400230P.
PR 01-AUG-2002; 2002US-0400268P.
PR 01-AUG-2002; 2002US-0400363P.
PR 01-AUG-2002; 2002US-0400365P.
PR 01-AUG-2002; 2002US-0400374P.
PR 01-AUG-2002; 2002US-0400380P.
PR 01-AUG-2002; 2002US-0400433P.
PR 01-AUG-2002; 2002US-0400434P.
PR 01-AUG-2002; 2002US-0400436P.

PR 01- AUG-2002; 2002US-0400442P.
 PR 01- AUG-2002; 2002US-0400463P.
 XX
 PA (AFFI -) AFFINUM PHARM INC.
 XX
 PI Edwards A, Dharmsri A, Vedadi M, Vallee F, Awrey D, Beattie B;
 PI Richards D, Domagala M, Mansoury K, Virag C, Buzadzija K;
 PI McDonald M, Houston S, Arrowsmith C, Quyang H, Netherly K, Ng I;
 PI Kanagarajah D;
 XX
 WPI : 2004-071165/07.
 DR-PSDB; ADH97014.
 XX
 PT Compositions comprising recombinant polypeptide targets for pathogenic
 bacteria, useful for designing modulators for preventing or treating a
 disease or disorder associated with the species of origin for the
 polypeptide.
 XX
 PS Claim 23; SEQ ID NO 204; 606pp; English.
 XX
 CC The invention relates to novel compositions (1) comprising isolated,
 recombinant polypeptides, amino acid sequences having at least about 95%
 identity with these or an amino acid sequence encoded by a polynucleotide
 that hybridizes under stringent conditions to the complementary strand of
 the polynucleotide encoding these polypeptides. The compositions and
 polypeptides are useful as microbial targets for designing modulators for
 the prevention or treatment of a disease or disorder associated with the
 species of origin for the polypeptide, e.g. furuncle, pneumonia,
 gastritis, peptic ulcer disease, diarrhoea, meningitis, bacteraemia,
 conjunctivitis or toxic shock syndrome. The polypeptides are also useful
 for diagnosing a patient suffering from a disease or disorder of a
 pathogenic species, or for monitoring the effectiveness of an anti-
 pathogenic treatment. This sequence corresponds to one of the DNA
 sequences of the invention
 XX
 SQ Sequence 1110 BP; 341 A; 211 C; 267 G; 291 T; 0 U; 0 Other;
 Query Match 10.3% Score 78; DB 12; Length 1110;
 Best Local Similarity 50.7% Pred. No. 8.1e-14;
 Matches 214; Conservative 0; Mismatches 205; Indels 3; Gaps 1;
 Qy 31 CCATTTCTGACCAATGACCAAGTGAAAGATTGATAGCCAAAGAGCAGCTGGGATAAG 90
 Db 328 CCTCTCTTGACCAATGAAGAGAGAAAGAGTTGGCACTGGCTGTGAAGCTGGTATAC 387
 Qy 91 GATGCAOGT GAGCTTCCTCGTGAATAGCAATATCAGACTGGCTCTGGTCGCGTGTGCGGC 150
 Db 388 GAAGCCAAACAAACGCTTGGGAAACCCAACTTCGTTGGITGTTCCATTGCAAAACGCG 447
 Qy 151 TTTATCAACCGCGGGTATGAAAGGGATGATTTGTTCAAGATCGTTGCAATTGGCTTGTC 210
 Db 448 TATGTCGGTGTGTGGCATGGAGTCCTTGACTTGATTCAAGAAGGAAATATGGCTTGATG 507
 Qy 211 AAGGCCGTTGACAAGTTCGATCTTCTGACCATGTCAGATTTGGACCTATGGGTGCGCA 270
 Db 508 AAGGCCGTTGACAAGTTGACTTCTAAAGGGTTCAAGTTCACATTGCAACATTGG 567
 Qy 271 ATGATCATCGGAGAAAT--TCAACCGCTTTTGGGGCATGACGGTACGGTTAACGGTCAGT 327
 Db 568 TGGATTOGTCAGGCTATCACTCGTGTATTGGGACCAACCTGCTACCATCGGTATCCCA 627
 Qy 328 CGATCGTTAAAGAACAGCGAAATAGGTGGGGCATCAAGGATGAATTGTACAAGCAA 387
 Db 628 GTTCACATGGTTGAAACTATCAAAATGTTGTTGTTGAAACAGCGGAATCTCTTCAAGAA 687
 Qy 388 TTGGGCGTGCCCCACGATGGCAGAAGTGGCAGAACGAGTGGGAATCACGGGAGGAA 447
 Db 688 TTGGGCGCAAGATCGACACAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747

Qy 448 GT 449
||
Db 748 GT 749

RESULT 8
AEC13368
ID AEC13368 standard; DNA; 1110 BP.
XX
AC AEC13368;
XX
DT 20-OCT-2005 (first entry)
XX
DE Streptococcus pneumoniae RNA polymerase sigma-70 factor gene.
XX
KW protein purification; antibacterial; antimicrobial; infection;
KW drug screening; RNA polymerase sigma-70 factor; gene; ss.
XX
OS Streptococcus pneumoniae.
XX
PN US2005181464-A1.
XX
PD 18-AUG-2005.
XX
PF 29-SEP-2004; 2004US-00953901.
XX
PR 04-APR-2002; 2002US-0369819P.
PR 04-APR-2002; 2002US-0369826P.
PR 04-APR-2002; 2002US-0369831P.
PR 04-APR-2002; 2002US-0370060P.
PR 08-APR-2002; 2002US-0370681P.
PR 08-APR-2002; 2002US-0370806P.
PR 08-APR-2002; 2002US-0370852P.
PR 08-APR-2002; 2002US-0370868P.
PR 09-APR-2002; 2002US-0370959P.
PR 09-APR-2002; 2002US-0370978P.
PR 09-APR-2002; 2002US-0371008P.
PR 09-APR-2002; 2002US-0371009P.
PR 09-APR-2002; 2002US-0371014P.
PR 09-APR-2002; 2002US-0371025P.
PR 09-APR-2002; 2002US-0371064P.
PR 09-APR-2002; 2002US-0371065P.
PR 09-APR-2002; 2002US-0371094P.
PR 09-APR-2002; 2002US-0371114P.
PR 09-APR-2002; 2002US-03711180P.
PR 09-APR-2002; 2002US-03711189P.
PR 31-MAY-2002; 2002US-0384634P.
PR 31-MAY-2002; 2002US-0385157P.
PR 04-JUN-2002; 2002US-0386542P.
PR 04-JUN-2002; 2002US-0385611P.
PR 04-JUN-2002; 2002US-0385747P.
PR 04-JUN-2002; 2002US-0385750P.
PR 04-JUN-2002; 2002US-0385752P.
PR 04-JUN-2002; 2002US-0385773P.
PR 04-JUN-2002; 2002US-0385780P.
PR 04-JUN-2002; 2002US-0385785P.
PR 04-JUN-2002; 2002US-0385797P.
PR 05-JUN-2002; 2002US-0385962P.
PR 05-JUN-2002; 2002US-0386022P.
PR 05-JUN-2002; 2002US-0386024P.
PR 05-JUN-2002; 2002US-0386087P.
PR 05-JUN-2002; 2002US-0386141P.
PR 05-JUN-2002; 2002US-0386350P.
PR 05-JUN-2002; 2002US-0386586P.
PR 06-JUN-2002; 2002US-0386368P.
PR 06-JUN-2002; 2002US-0386369P.
PR 06-JUN-2002; 2002US-0386436P.
PR 06-JUN-2002; 2002US-0386441P.
PR 06-JUN-2002; 2002US-0386528P.

PR 06-JUN-2002; 2002US-0386573P.
 PR 06-JUN-2002; 2002US-0386834P.
 PR 31-JUL-2002; 2002US-0399839P.
 PR 31-JUL-2002; 2002US-0399861P.
 PR 31-JUL-2002; 2002US-0399969P.
 PR 31-JUL-2002; 2002US-0399970P.
 PR 31-JUL-2002; 2002US-0399983P.
 PR 31-JUL-2002; 2002US-0399984P.
 PR 31-JUL-2002; 2002US-0399985P.
 PR 01-AUG-2002; 2002US-0400154P.
 PR 01-AUG-2002; 2002US-0400230P.
 PR 01-AUG-2002; 2002US-0400268P.
 PR 01-AUG-2002; 2002US-0400363P.
 PR 01-AUG-2002; 2002US-0400365P.
 PR 01-AUG-2002; 2002US-0400374P.
 PR 01-AUG-2002; 2002US-0400380P.
 PR 01-AUG-2002; 2002US-0400433P.
 PR 01-AUG-2002; 2002US-0400434P.
 PR 01-AUG-2002; 2002US-0400436P.
 PR 01-AUG-2002; 2002US-0400442P.
 PR 01-AUG-2002; 2002US-0400463P.
 PR 04-APR-2003; 2003WO-CA000465.
 08-APR-2003; 2003WO-CA000482.
 08-APR-2003; 2003WO-CA000483.
 02-JUN-2003; 2003WO-CA000786.

XX

(AFFI -) AFFI NI UM PHARM INC.

XX

PEdwards A, Dharansi A, Vedadi M, Al am MZ, Arrowsmith C, Awrey DE;
 Beattie B, Buzadzija K, Clarke T, Domagala M, Houston S;
 Kanagarajah D, Li Q, Mansoury K, McDonald M, Nethey- Brocks K, Ng I;
 Quyang H, Richards D, Vallee F, Virag C,

XX

WIPI: 2005-628190/64.
 DR-PSDB; AEC13369.

XX

PT Novel crystallized, recombinant bacterial polypeptide, useful as target s for pathogenic bacteria such as *Helicobacter pylori*, *Staphylococcus aureus*, for detecting pathogenic species in biological sample, and in drug design gning.

XX

PS Claim 85; SEQ ID NO 204; 637pp; English.

XX

The invention relates to a composition (1) comprising purified polypeptides from bacteria. Also described: (1) a crystallized, recombinant polypeptide comprising an amino acid sequence of (1), where the polypeptide is in crystal form (2) a crystallized complex comprising the crystallized, recombinant polypeptide and a co-factor or a small organic molecule, where the complex is in crystal form, and (3) a host cell comprising a nucleic acid encoding a polypeptide of (1), where a culture of the host cell produces at least about 1 mg of the polypeptide per liter of culture and the polypeptide is at least about one-third soluble as measured by gel electrophoresis. (1) can be used as a target for pathogenic bacteria, useful for detecting the presence of a pathogenic species in a biological sample. (1) is useful for monitoring the effectiveness of anti-pathogenic treatments in an individual suffering from a disease or disorder caused by a pathogenic bacteria, such as infections. (1) is also useful in drug design and screening, for identifying inhibitors of (1), for designing a potential compound that is useful for treating or preventing pathogenic diseases or disorders, for assessing the activity of small molecules and other modulators in *in vitro* assay, and for developing antimicrobial agents. The present sequence represents a *Streptococcus pneumoniae* RNA polymerase sigma-70 factor gene, which is used in an example from the present invention.

XX

SQ Sequence 1110 BP; 341 A; 211 C; 267 G; 291 T; 0 U; 0 Other;

Query Match 10.3% Score 78; DB 18; Length 1110;
 Best Local Similarity 50.7% Pred. No. 8.1e-14;

Mat ches	214;	Conser vative	0;	M smatches	205;	I ndel s	3;	Gaps	1;
Qy	31	CCATTCTGACCAATGACCAAGTGAAGATTTGATAGCCAAGAGCAAGCTGGCGATAACG	90						
Db	328	CCCTCTTGAACCAATGAAGAGAGAAAGACTGGCACTGGCTGTTGAACCTGGTGTATC	387						
Qy	91	GATGCAOGTGACCTTCTCGTGAATAGCAATATCAGACTGGCTGGTCCGGTGTGTCAGGGC	150						
Db	388	GAAGCCAAACAAACGCTTGGGAAACCAATCTTCGTTGGTGTTCATTGCGCTGCTC	447						
Qy	151	TTTATCAACCGGGGTATGAAGGGATGATTTGTTTCAAGATGGTTCCATTGCGCTGCTC	210						
Db	448	TATGTCGGTGTGGCATGGAGTTCTTGACTTGAATTCAAGAAGGAAATATGGGTTGATG	507						
Qy	211	AAAGGCGTTAACAGITGGATCTTCTGTAACGATGAGATTTGACCTATGGGTGCGA	270						
Db	508	AAAGGCGTTAACAGITGGACTTCAAGTTCTAAAGGGTTCAAGITTTCAACTTATGCAACTTGG	567						
Qy	271	ATGATCATOGGAGAAAT--TCAACGGCTTTTGCGCGATGAOGGTACGGTTAAGGGTCACT	327						
Db	568	TGGATTGGTCAAGCTATCACTCGTGTATTGCGGACCAAGCTCGTACCATCGTATCCCA	627						
Qy	328	CGATCGTTAAAGAAACCGGATAAAGGTGGCGGATCAAAGGATGAATTGTACAACCAA	387						
Db	628	GTTCACATCGTTGAAACTATCAATAATTGGTTGGTGAACAGCGGAATCTCTTCAGAA	687						
Qy	388	TTGGCGGTGCGGGCACGATCGAGAAGTGGCGAGAACCGAGTGGGAATCACGGGAGGAA	447						
Db	688	TTGGCGCAAGATCGAACACAGAACAGATTGCTGAACGATGGATATGACACCTGATAAG	747						
Qy	448	GT 449							
Db	748	GT 749							

RESULT 9

ADK44581

ID ADK44581 standard; DNA; 915 BP.

XX

AC ADK44581;

XX

DT 24-FEB-2005 (first entry)

XX

DE Streptococcus pneumoniae gene, Seq ID No 1096.

XX

KW ds; gene; Antibacterial; Gene therapy; Vaccine; Streptococcus pneumoniae.

XX

OS Streptococcus pneumoniae.

XX

PN US6699703-B1.

XX

PD 02-MAR-2004.

XX

PF 26-MAY-2000; 2000US-00583110.

XX

PR 02-JUL-1997; 97US-0051553P.

PR 12-MAY-1998; 98US-0085131P.

PR 30-JUN-1998; 98US-00107433.

XX

PA (GENO) GENOME THERAPEUTICS CORP.

XX

PI Doucette-E-Stamm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI; 2004-212399/20.

DR-PSDB; ADK47242.

XX

PT New nucleic acid molecules and polypeptides useful for diagnosing,

PT preventing and treating pathological conditions resulting from bacterial

PT infection, e.g. Streptococcus pneumoniae infection, and in drug

PT screening.

XX Disclosure; SEQ ID NO 1096; 301pp; English.

XX
The invention relates to isolated Streptococcus pneumoniae nucleic acids and polypeptides. The nucleic acids and proteins are useful for diagnosing, preventing and treating pathological conditions resulting from bacterial infection, such as S. pneumoniae infection. These may also be used for drug screening procedures. The present sequence represents a Streptococcus pneumoniae nucleic acid of the invention. Note: The sequence data for this patent did not appear in the printed specification but was obtained in the electronic format directly from USPTO at seqdat.uspto.gov/sequence.htm.

XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query	Match	10.1%	Score 76.4;	DB 12;	Length 915;
Best	Local Similarity	50.5%	Pred. No. 2,4e-13;		
Matches	Conservative	0;	Mismatches	206;	Indels 3;
					Gaps 1;

Qy	31	CCATTTCTGACCAATGACCAAGTGAAGAAGATTGATAGCCAAAGGCCAAGCTGGGATAAG 90
Db	328	CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTGAAGCTGGTGTATC 387
Qy	91	GATGCACTGTGAGCTTCTCGTGAATAGCAATATCAGACTGGCTGGTCCGGTGGTGGTGGC 150
Db	388	GAAGCCAAACAAACGCTTGGGAGGCCAATCTTGTGTTGGTTGTGTTCCATTGCCAAACGC 447
Qy	151	TTTATCAAACCGGGTATGAAGGCGATGATTTGTTTCAAGATGGTTGATTGGCTTGGCTC 210
Db	448	TATGTCGGTGTGTATGCAAGTTGACTTGTGATTCAAGAAGGAAATATGGCTTGTG 507
Qy	211	AAGGCCGTTGACAAGTTCGATCTTCTGTAAGATGTGAGATTTOGACCTATGGGTGCCA 270
Db	508	AAGGCCGTTGACAAGTTGACTTCTAAAGGGTCAAGTTCAACTTATGCCAACTTGG 567
Qy	271	ATGATCATCGAGAAATTCAACCCCTTTTGGCGATGAOG--GTACGGTTAAGGTCAGT 327
Db	568	TGGATTGGTCAAGCTATCACTCGTCTATTGCAAGACCAAGCTGTCACCATCGTATCCCA 627
Qy	328	CGATCGTTAAAGAAACAGGAAATAAGGTGGGGATCAAGGATGAATTGTACAAGCAA 387
Db	628	GTTACATCGTTGAAACTATCAATAAAATTGGTGTGATGAAACAGGAAATCTCTTCAAGAA 687
Qy	388	TTGGGCGGTGCCCCACGATGCCAGAAGTGGCAGAACAGCTGGGAATCAACGGGAGGAA 447
Db	688	TTGGGCGCAAGATCGAACACCAAAACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747
Qy	448	GT 449
Db	748	GT 749

RESULT 10

AEJ68509

ID AEJ68509 standard; DNA; 915 BP.

XX

AC AEJ68509;

XX

DT 05-OCT-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccines; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW anti-bacterial; neuropeptide; anti-inflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..915
 FT /*tag= a
 FT /product = "Streptococcus pneumoniae protein SEQ ID
 FT NO:3757"
 XX
 PN US7074914- B1.
 XX
 PD 11-JUL-2006.
 XX
 PF 30-DEC-2004; 2004US-00028099.
 XX
 PR 02-JUL-1997; 97US-0051553P.
 PR 12-MAY-1998; 98US-0085131P.
 PR 30-JUN-1998; 98US-00107433.
 PR 26-MAY-2000; 2000US-00583110.
 PR 14-AUG-2003; 2003US-00640833.
 XX
 PA (SNFI) SANOFI PASTEUR LTEE.
 XX
 PI Doucette- Stamm L, Bush D, Zeng Q, Opperman T, Housewright CE;
 XX
 DR WPI ; 2006-500481/51.
 DR P-PSDB; AEJ71170.
 XX
 PT New isolated nucleic acid and polypeptide from Streptococcus pneumoniae,
 PT useful for diagnosing, preventing, or treating pathological conditions
 PT resulting from bacterial infections, e.g. S. pneumoniae infection.
 XX
 Exemplar; SEQ ID NO 1096; 29pp; English.
 XX
 CC The invention relates to an isolated nucleic acid, especially (AEJ68056),
 CC which encodes the Streptococcus pneumoniae protein of AEJ7017. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEJ67414-AEJ70074) isolated from a Streptococcus pneumoniae strain 14453
 CC genome library whose predicted products (AEJ70075-AEJ72735) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 CC preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus
 CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation
 CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdata.uspto.gov/sequence.htm?DocID=7074914B1.
 XX
 SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;
 XX
 Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;
 Qy 31 CCATTTCTGACCAATGACCAAGTGAAAGATTGATAGCCAGAGCCAGCTGGCGATAAG 90
 Db 328 CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTGAGCTGGTGTATC 387

Qy 91 GATGCAOGT GAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGGTCCAGGGC 150
 Db 388 GAAGCACAACAAACGCTTCTGGAGCCAACTTCTCGTTCTTGTGTTCCATTGGCTTGCTC 447
 Qy 151 TTTATCAACCGGGGTATGAAACGGGATGATTGTTTCAAGATGGTCCATTGGCTTGCTC 210
 Db 448 TATGTCGGTGTGTTGCAAGGTTCTTGACTTCAAGAAGGAAATATGGCTTGATG 507
 Qy 211 AAGGCCGTTGACAAGTTGATCTTCTGTAACGATGAGATTTTCAACCTATGGCTGCCA 270
 Db 508 AAGGCCGTTGACAAGTTGACTTCAAAAGGTTCAAGTTTCAACTTATGCAACTTGG 567
 Qy 271 ATGATCATCGAGAAATTCAACCCCTTTTGGCGCATGACG -- GTACCGGTTAAGGTCACT 327
 Db 568 TGATGATGTCAGGCTATCACTCGTCTATTGCAACAAAGCTGCTACCATCGTATCCCA 627
 Qy 328 CGATCGTTAAAAGAAACAGCGAATAAGGTGGCGCGATCAAAGGATGAATTGTACAAGCAA 387
 Db 628 GTTCACATGGTTGAAACTATCAATAATTGCGTTGTTGAAACAGCGGAATCTCCTCAAGAA 687
 Qy 388 TTGGCGGTGCCCGCAAGATCGCAGAAGTGGCAAGAGCTGGGAATCACCGGGAGAA 447
 Db 688 TTGGCGCAAGATCGACACAGAACAGATTGCTGAAAGAATGGATATGACACGTGATAAG 747
 Qy 448 GT 449
 Db 748 GT 749

RESULT 11

AEJ75484

ID AEJ75484 standard; DNA; 915 BP.

XX

AC AEJ75484;

XX

DT 05-OCT-2006 (first entry)

XX

Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

Vaccine; diagnosis; drug discovery; protein production;

bacterial infection; Streptococcus pneumoniae infection;

bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

bacterial; neoprotective; antiinflammatory; respiratory-gen.;

auditory; gene; ds.

XX

Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

FT /tag= a

FT /product = "Streptococcus pneumoniae protein SEQ ID

FT NO: 3757"

XX

PN US7081530-B1.

XX

PD 25-JUL-2006.

XX

PF 30-DEC-2004; 2004US-00028291.

XX

PR 02-JUL-1997; 97US-0051553P.

PR 12-MAY-1998; 98US-0085131P.

PR 30-JUN-1998; 98US-00107433.

PR 26-MAY-2000; 2000US-00583110.

PR 14-AUG-2003; 2003US-00640833.

XX

PA (SNFI) SANOFI PASTEUR LTEE.

XX

PI Doucette-Stramm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI : 2006-518920/ 53.
 DR P-PSDB; AEJ78145.

XX
 PT New isolated Streptococcus pneumoniae nucleic acid, useful as a molecular target for detecting, diagnosing, preventing, or treating a pathological condition resulting from bacterial infection.
 XX

PS Example; SEQ ID NO 1096; 29pp; English.
 XX

CC The invention relates to an isolated nucleic acid, especially (AEJ75443), which encodes the Streptococcus pneumoniae protein of AEJ78104. This nucleic acid is one of 2661 disclosed protein-encoding nucleic acids (AEU74389-AEJ77049) isolated from a Streptococcus pneumoniae strain 14453 genomic library whose predicted products (AEJ77050-AEJ79710) exhibit homology to known prokaryotic, eukaryotic or archaeal open reading frames (ORFs) or proteins. The invention also relates to a recombinant expression vector comprising the nucleic acid of the invention operably linked to a transcription regulatory element; and a host cell comprising the recombinant expression vector. The Streptococcus pneumoniae nucleic acids and proteins of the invention are useful for diagnosing, preventing, or treating pathological conditions resulting from bacterial infections, especially infections caused by Streptococcus pneumoniae such as meningitis, bacteremia, pneumonia and otitis media. They may also be used in vaccine compositions for the treatment of Streptococcus pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of commercially important proteins such as enzymes for use in fermentation reactions or in the production of commercially useful metabolites. The present sequence represents a Streptococcus pneumoniae strain 14453 protein-encoding nucleic acid which was identified in the exemplification of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from the US patent office at
 CC seqdata.uspto.gov/sequence.htm?DocID=7081530B1.
 XX

Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2, 4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

Qy	31	CCATTTCTGACCAATGACCAAGTGAAAGATTGATAGCCAAAGAGCAAGCTGGGATAAG	90
Db	328	CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTGAAGCTGGTATAC	387
Qy	91	GATGCAOGTGAGCTTCCTGTTGAATAGCAATATCAGACTGGCTGGTCTCGTGTGTCAGCGC	150
Db	388	GAAGCCAAACAAACGCTTGGGAAGCCAACTTCGTTGGITGTTCCATTGCAAAACGC	447
Qy	151	TTTATCAACCGCGGGTATGAAAGGGATGATTGTTGTTAGATCGTTGCAATTGGCTTGTC	210
Db	448	TATGTCGGTGTGTGTATGCAAGTCTTCGACTTGCCTTGACTTGATTCAAGAAGGAAATATGGCTTGATG	507
Qy	211	AAGGCCGTTGACAAGTTCGATCTTCTGACCATGTCAGATTTGGACCTATGGGGTGCA	270
Db	508	AAGGCCGTTGACAAGTTGACTTCTAAAGGGTTCAAGTTCACATTGCAACATTGG	567
Qy	271	ATGATCATCGGAGAAATTCAACCGTTTGGGGCATGACG--GTACCGGTTAACGGTCAGT	327
Db	568	TGGATTOGTCAAGCTTATCACTCGTGTATTGCAACACCAACCTGCTACCATCGTATCCCA	627
Qy	328	CGATCGTTAAAGAACAGCGAAATAGGTGGGGATCAAGAGTGAATTGTACAAGCAA	387
Db	628	GTTACATGGTTGAAACTATCAATAATTGTTGTTGAAACAGCGGAATCTCCCTCAAGAA	687
Qy	388	TTGGGGCGTGCCCCACGATCGGAGAGTGGCGACAAGGAGTGGGAATCAACGGGAGGAA	447
Db	688	TTGGGCGCAAGATCGACACCGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG	747

Qy 448 GT 449
 Db 748 GT 749

RESULT 12

AEJ82844

ID AEJ82844 standard; DNA; 915 BP.

XX

AC AEJ82844;

XX

DT 19-CCT-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacteremia; bacteremia; otitis media;

KW antibacterial; neoprotective; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

FT /*tag= a

FT /product = "Streptococcus pneumoniae protein SEQ ID

FT NO:3757"

XX

PN US7098023-B1.

XX

PD 29-AUG-2006.

XX

PF 30-DEC-2004; 2004US-00027878.

XX

PR 02-JUL-1997; 97US-0051553P.

PR 12-MAY-1998; 98US-0085131P.

PR 30-JUN-1998; 98US-00107433.

PR 26-MAY-2000; 2000US-00583110.

PR 14-AUG-2003; 2003US-00640833.

XX

PA (SNFI) SANOFI PASTEUR LTD.

XX

PI Doucette E, Starmann L, Bush D, Zeng Q, Cpperman T, Houseweart OE;

XX

DR WPI; 2006-584390/60.

DR P-PSDB; AEJ85505.

XX

PT New isolated Streptococcus pneumoniae nucleic acid and polypeptide, useful as vaccines and as targets for diagnosing, preventing, or treating pathogenic conditions resulting from S. pneumoniae bacterial infection.

XX

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEJ84330), which encodes the Streptococcus pneumoniae protein of AEJ86991. This nucleic acid is one of 2661 disclosed protein-encoding nucleic acids (AEU81749-AEJ84409) isolated from a Streptococcus pneumoniae strain 14453 genomic library whose predicted products (AEU84410-AEJ87070) exhibit homology to known prokaryotic, eukaryotic or archaeal open reading frames (ORFs) or proteins. The invention also relates to a recombinant expression vector comprising the nucleic acid of the invention operably linked to a transcription regulatory element; and a host cell comprising the recombinant expression vector. The Streptococcus pneumoniae nucleic acids and proteins of the invention are useful for diagnosing, preventing, or treating pathogenic conditions resulting from bacterial infections, especially infections caused by Streptococcus pneumoniae such as meningitis, bacteremia, pneumonia and otitis media. They may also be used in vaccine compositions for the treatment of Streptococcus

CC pneumonias infections and as targets for anti bacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation
 CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdat.uspto.gov/sequence.htm?DocID=7098023B1.
 XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2,4e-13;
 Matches 213; Conservative 0; M matches 206; Indels 3; Gaps 1;

Qy	31	CCATTTCTGACCAATGACCAAGTGAAGAGATTGATAGCCAAGAGCCAAGCTGGCGATAAG 90
Db	328	CCCTCTTGAACCAATGAAGAGGAGAAAAGAGCTGGCACTGGCTGTTGAACCTGGTGTATC 387
Qy	91	GATCCAGTGAAGTTCTCGTGAATAGCAATATCAGACTGGCTGGTGGTGGTGGTGGTGGC 150
Db	388	GAAGCCAAACAAAGCTTGGGAAGCCAATCTTGGTGGTGGTGGTGGTGGTGGTGGTGGC 447
Qy	151	TTTATCAACCGGGGTATGAAGGGATGATTTGGTTTCAAGATGGTTGGTGGTGGTGGC 210
Db	448	TATGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGC 507
Qy	211	AAGGCGGTTGACAAGTTGACTCTTGGTGAAGATGGTGGTGGTGGTGGTGGTGGTGGC 270
Db	508	AAGGCGGTTGACAAGTTGACTCTTGGTGAAGATGGTGGTGGTGGTGGTGGTGGC 567
Qy	271	ATGATCATGGAGAAATTCAACGGTTGGCGATGAGTGTGGATGGTGGTGGTGGTGGC 327
Db	568	TGGATTGGTCAAGCTATCAGTGGTGTATTGGTGGTGGTGGTGGTGGTGGTGGC 627
Qy	328	GGATGGTAAAGAAACAGGGAATAAGGTGGGGGATCAAAGGGATGAATTGTACAAGGAA 387
Db	628	GGTCACATGGTGAACATATCAATAAAATTGGTGGTGGTGAACAGGGGAATCTCCTTCAGAA 687
Qy	388	TTGGCGGTGCCCCACAGATGGCAGAAGTGGCAGAAGCAGTGGGAATCAAGGGAGAA 447
Db	688	TTGGGCAAGATGGACACACAGAACAGATTGGTGAACGAATGGATGACACCTGATAAG 747
Qy	448	GT 449
Db	748	GT 749

RESULT 13

AEL05163

ID AEL05163 standard; DNA; 915 BP.

XX

AC AEL05163;

XX

DT 30-NOV-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein product ion;

KW bacteri al infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW anti bacterial; neuropeptide; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

CS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915
 FT /* tag= a
 FT /product= "Streptococcus pneumoniae protein SEQ ID
 FT NO: 3757"
 XX
 PN US7115731-B1.
 XX
 PD 03- OCT- 2006.
 XX
 PF 30- DEC- 2004; 2004US- 00027399.
 XX
 PR 02- JUL- 1997; 97US- 0051553P.
 PR 12- MAY- 1998; 98US- 0085131P.
 PR 30- JUN- 1998; 98US- 00107433.
 PR 26- MAY- 2000; 2000US- 00583110.
 PR 14- AUG- 2003; 2003US- 00640833.
 XX
 PA (SNFI) SANOFI PASTEUR LTD.
 XX
 PI Doucette- Stamm L, Bush D, Zeng Q, Opperman T, Housewright OE;
 XX
 DR WPI : 2006-744050/76.
 DR P-PSDB; AEL07824.
 XX
 PT New nucleic acid encoding Streptococcus pneumoniae polypeptide, useful
 PT for detecting, preventing, and treating pathological conditions resulting
 PT from bacterial infection.
 XX
 PS Example; SEQ ID NO 1096; 29pp; English.
 XX
 CC The invention relates to an isolated nucleic acid, especially (AEL05123),
 CC which encodes the Streptococcus pneumoniae protein of AEL07784. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEL04068-AEL06728) isolated from a Streptococcus pneumoniae strain 14453
 CC genomic library whose predicted products (AEL06729-AEL09389) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus
 CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation
 CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdat.uspto.gov/sequence.htm?DocID=7115731B1.
 XX
 SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;
 Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2_4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;
 Qy 31 CCATTTCTGACCAATGACCAAGTGAAGATTTGATGCGCAAGAGCGCAAGCTGGCGATACTGCGATACG 90
 Db 328 CCTCTCTTGAACCAATGAAGAGGAGAAAAGAGCTTGGCACTGGCTGTGGAACCTGGTGTATC 387
 Qy 91 GATGCACTGAGCTTCTCGTGAATAGCAATATCAGACTGGCTGGCTCGTGTGTCAGGC 150
 Db 388 GAAGCCAAACAACTGCTTCCGAAACCAATCTTGTCTGGTGTGTTGATTCATTGCCAAACGC 447

Qy 151 TTTATCAAACCGGGATGAAGCGGATGATTTGTTCAAGATGGTTCCATTGGCTTGTC 210
 Db 448 TATGTGGTGTGTTGAGTCTTGTGACTTGAAGAAGGAAATATGGCTTGATG 507
 Qy 211 AAGGCCGTTGACAAGTTGATCTTCTGACATGTGAGATTTCGACCTATGCGGTGCA 270
 Db 508 AAGGCCGTTGACAAGTTGACTTAAAGGTTCAAGTTCAACTTATGCAACTTGG 567
 Qy 271 ATGATCATCGAGAAATTCAACCTTTTGCGCGATGAAG- - GTACGGTTAAGGTCACT 327
 Db 568 TGCGATGGTCAAGCTATCACTCGTCTATTGCAAGACCAAGCTCGTACCCATCGTATCCCA 627
 Qy 328 CGATCGTTAAAGAAAACAGCGAATAAGGTGGCGGATCAAAGGATGAATTGTACAAGAA 387
 Db 628 GTTCACATCGGTTGAAACTATCAATAAAATTGGTTGTGAACAGCGGAATCTCTTCAGAA 687
 Qy 388 TTGCGCGGTGCGGGCGAAGATCGCGAGTGGCAGACAAGGAGTGGGAATCACGGGAGGAA 447
 Db 688 TTGGCGCAAGATCGACACCAAGAACAGATTGCTGAACGAATGGATATGACAACGTATAAG 747
 Qy 448 GT 449
 Db 748 GT 749

RESULT 14

AEL12413

ID AEL12413 standard; DNA; 915 BP.

XX

AC AEL12413;

XX

DT 28-DEC-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibacterial; neuroprotective; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

CS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

/*tag= a

FT product= "Streptococcus pneumoniae protein SEQ ID

NO: 3757"

XX

PN US7122368-B1.

XX

PD 17-OCT-2006.

XX

PF 30-DEC-2004; 2004US-00027877.

XX

PR 02-JUL-1997; 97US-0051553P.

PR 12-MAY-1998; 98US-0085131P.

PR 30-JUN-1998; 98US-00107433.

PR 26-MAY-2000; 2000US-00583110.

PR 14-AUG-2003; 2003US-00640833.

XX

PA (SNFI) SANOFI PASTEUR LTD.

XX

PI Doucette-Stramm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI : 2006-812612/82.

DR P-PSDB; AEL15074.

XX

PT New isolates nucleic acid and polypeptides isolated from strain 14453 of *Streptococcus pneumoniae*, useful for diagnosing, preventing, or treating bacterial infections, e.g. *S. pneumoniae* infection.

XX

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEL12919), which encodes the *Streptococcus pneumoniae* protein of AEL15580. This nucleic acid is one of 2661 disclosed protein-encoding nucleic acids (AEL11318-AEL13978) isolated from a *Streptococcus pneumoniae* strain 14453 genomic library whose predicted products (AEL13979-AEL16639) exhibit homology to known prokaryotic, eukaryotic or archaeal open reading frames (ORFs) or proteins. The invention also relates to a recombinant expression vector comprising the nucleic acid of the invention operably linked to a transcription regulatory element; and a host cell comprising the recombinant expression vector. The *Streptococcus pneumoniae* nucleic acids and proteins of the invention are useful for diagnosing, preventing, or treating pathological conditions resulting from bacterial infections, especially infections caused by *Streptococcus pneumoniae* such as meningitis, bacteremia, pneumonia and otitis media. They may also be used in vaccine compositions for the treatment of *Streptococcus pneumoniae* infections and as targets for antibacterial drugs. Additionally the nucleic acids are useful in the production of commercially important proteins such as enzymes for use in fermentation reactions or in the production of commercially useful metabolites. The present sequence represents a *Streptococcus pneumoniae* strain 14453 protein-encoding nucleic acid which was identified in the exemplification of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from the US patent office at seqdata.uspto.gov/sequence.htm ?DocID=7122368B1.

XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query	Match	10.1%	Score 76.4;	DB 21;	Length 915;
Best	Local Similarity	50.5%	Score: 76.4;	DB: 21;	Length: 915;
Matches	213;	Conservative	0;	M matches	206;
				Indels	3;
				Gaps	1;
Qy	31	CCATTTCTGACCAATGACCAAGTGAAGAGATTGATGACCAAGAGCAGCAACCTGGGATAAG 90			
Db	328	CTCTCTTGTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTGAAAGCTGGTGTATTC 387			
Qy	91	GATGCACTGAGCTTCTGTAATAGCAATATCAGACTGCTCTGGTGGTGTGTCAGGGC 150			
Db	388	GAAGCCAAACAAAGCTTCTGGGAGGCCATCTTGTGTTGGTTCCATTGCCAAACGC 447			
Qy	151	TTTATCAACGGGGGTATGAAGGGATGATTTGTTTCAAGATGGTTGGTTCATTGGTTGGTC 210			
Db	448	TATGTCGGTGTGGTATGCCAGTCTTGTACTTCAAGAAGGAAATATGGCTTGTG 507			
Qy	211	AAGGCGGTTGACAAGITTCATTTGGGATGAAGTGTGAGATGGTTGGCTATGGGGCGCA 270			
Db	508	AAGGCGGTTGACAAGITTCAGTTGACTTAAAGGGTCAAGGTTCAACTTATGCCAATTGG 567			
Qy	271	ATGATCATGGAGAAATTCAACCTTTTGGGATGAOG -- GTACGGTTAACGTCAGT 327			
Db	568	TGGATTGTCAGGCTATCACTGGTCTATTGCAACGCCACCTCTAACATCGTATGCCA 627			
Qy	328	CGATCGTTAAAAGAAAAGCGGATAAAGGTGGGGGATCAAAAGGATGAATTGTACAAGGAA 387			
Db	628	GTTCACATGGTTGAAACTATCAATAAAATTGGTTGCTGAACAGGGAAATCTCCCTCAAGAA 687			
Qy	388	TTOGGGCGGTGCCCCCAAGATGGCAGAGTGGCAGAAGCAGTGGGAATCACCCGGAGGAA 447			
Db	688	TTGGGCGCAAGATGGCAGACACCAAGACAGATTGCTGAAGAATGGATATGACACGTGATAAG 747			
Qy	448	GT 449			
Db	748	GT 749			

RESULT 15

AEL50821

ID AEL50821 standard; DNA; 915 BP.

XX

AC AEL50821;

XX

DT 28- DEC- 2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ ID 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;
bacterial infection; Streptococcus pneumoniae infection;
bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;
antibacterial; neuroprotective; antiinflammatory; respiratory-gen.;
auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

FT /tag= a

FT /product= "Streptococcus pneumoniae protein SEQ ID
NO: 3757"

XX

PN US7129340-B1.

XX

PD 31- OCT- 2006.

XX

PF 30- DEC- 2004; 2004US-00028457.

XX

PR 02- JUL- 1997; 97US-0051553P.
PR 12- MAY- 1998; 98US-0085131P.
PR 30- JUN- 1998; 98US-00107433.
PR 26- MAY- 2000; 2000US-00583110.
PR 14- AUG- 2003; 2003US-00640833.

XX

PA (SNFI) SANOFI PASTEUR LTD.

XX

PI Doucette- Stamm L, Bush D, Zeng Q, Cpperman T, Housewright OE;

XX

DR WPI; 2006-812716/82.

DR -PSDB; AEL53482.

XX

PT New isolated nucleic acid and polypeptide isolated from Streptococcus pneumoniae, useful as components of antibacterial vaccines, and for diagnosis or treating S. pneumoniae and other Streptococcus infections.

XX

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEL52290), which encodes the Streptococcus pneumoniae protein of AEL54951. This nucleic acid is one of 2661 disclosed protein-encoding nucleic acids (AEL49726-AEL52386) isolated from a Streptococcus pneumoniae strain 14453 genomic library whose predicted products (AEL52367-AEL55047) exhibit homology to known prokaryotic, eukaryotic or archaeal open reading frames (ORFs) or proteins. The invention also relates to a recombinant expression vector comprising the nucleic acid of the invention operably linked to a transcription regulatory element; and a host cell comprising the recombinant expression vector. The Streptococcus pneumoniae nucleic acids and proteins of the invention are useful for diagnosing, preventing, or treating pathological conditions resulting from bacterial infections, especially infections caused by Streptococcus pneumoniae such as meningitis, bacteremia, pneumonia and otitis media. They may also be used in vaccine compositions for the treatment of Streptococcus pneumoniae infections and as targets for antibacterial drugs. Additionally the nucleic acids are useful in the production of commercially important proteins such as enzymes for use in fermentation

CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdata.uspto.gov/sequence.html?DocID=7129340B1.
 XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match	10.1%	Score	76.4;	DB	21;	Length	915;
Best Local Similarity	50.5%	Pred. No.	2,4e-13;				
Matches	213;	Conservative	0;	M matches	206;	Indels	3;
						Gaps	1;

Qy 31 CCATTTCTGACCAATGACCAAGTGAAGAGATTGATAGCCAAGAGGCAACCTGGGATAAG 90
 Db 328 CCTCTCTTGAACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTGTTGAAGCTGGTGTATTC 387
 Qy 91 GATGCCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGCTGGTCCGGTGGTCAAGGCGC 150
 Db 388 GAAGCCAAACAAAGCTTGGGGAGGCCAATCTTGTGTTGGTTGTGTTCCATTGCCAAACGC 447
 Qy 151 TTTATCAACCGCGGGTATGAAGCGGTATGATTTGTTTCAAGATGGGTTGCAATTGGCTTGTC 210
 Db 448 TATGTCGGTGGTGGTATGCCAGTTCTTGACTTGAATCAAGAAGGAAATATGGCTTGATG 507
 Qy 211 AAGGCGGTTGACAAGTTOGATCTTTCGTAOGATGTGAGATTTGGACCTATGGGGGCCA 270
 Db 508 AAGGCGGTTGACAAGTTGACTTATCTAAAGGGTCAAGTGGTCAACTTATGCAACTTGG 567
 Qy 271 ATGATCATGGAGAAATTCAACCTTTTGCGCGATGAOG--GTAAGGTTAAGGGTCACT 327
 Db 568 TGATTOGTCAAGGCTATCACTCGTGTATTGCAAGACCAAGCTCGTACCATCGTATCCCA 627
 Qy 328 CGATGTTAAAAGAAACAGGGAATAAGGTGGCGCGATCAAAGGATGAATTGTACAACGAA 387
 Db 628 GTTCACATGGTTGAAACTATCAATAAAATGGTTGCTGAACAGCGGAATCTCCTTCAAGAA 687
 Qy 388 TTGGGGCGTGCGGGCGCAAGATCGCGAGTGGCAGAAGCAGTGGGAATCACGGGAGGAA 447
 Db 688 TTGGGGCAAGATCGGACACCGAACAGATTGCTGAAGGAATGGATATGACAACTGATAAG 747
 Qy 448 GT 449
 Db 748 GT 749

Search completed: November 4, 2008, 17:14:39
 Job time : 247 secs

SCORE 3.0